HCVcc-IN-1

HCVcc-IN-1 (compound 8c) (0.1, 1, 10, and 100 μg/mL; 1 h) shows antiviral activities against a variety of viruses such as coxsackievirus B4 (CBV4), hepatitis A virus HM 175 (HAV), hepatitis C genotype 4 (HCVcc), adenovirus type 7 (HAdV7), and herpes simplex virus 1 (HSV-1) with viral reduction rates of 86.7%, 66.7%, 23.3%, 66.7%, and 36.7%, respectively^[1].
HCVcc-IN-1 (0.57-2.0 μg/mL; 1 h) inhibits various virus with IC₅₀ of 0.57 μg/mL (herpes simplex virus), 0.71 μg/mL (HCVcc genotype virus), and 0.69 μg/mL (coxsackievirus B4), respectively; or with CC₅₀ of 2.0 μg/mL (herpes simplex virus), 1.7 μg/mL (HCVcc genotype virus), and 1.7 μg/mL (coxsackievirus B4), respectively^[1].
HCVcc-IN-1 (5.16-7.23 μg/mL) inhibits hepatitis C virus NS3/4A and HSV-USP7 protease enzyme with IC₅₀s of 5.16 μg/mL and 7.23 μg/mL^[1].
HCVcc-IN-1 (0.01 mM; 24 h) has low cytotoxicity against FRHK-4, Hep2, BGM, Vero, and Huh 7.5 cell lines^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.